ATE124047T1 - Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen. - Google Patents

Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.

Info

Publication number
ATE124047T1
ATE124047T1 AT91403116T AT91403116T ATE124047T1 AT E124047 T1 ATE124047 T1 AT E124047T1 AT 91403116 T AT91403116 T AT 91403116T AT 91403116 T AT91403116 T AT 91403116T AT E124047 T1 ATE124047 T1 AT E124047T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical compositions
compositions containing
oxazolopyridine
derivatives
Prior art date
Application number
AT91403116T
Other languages
English (en)
Inventor
Gerald Guillaumet
Christine Flouzat
Michelle Devissaguet
Pierre Renard
Daniel Henri Caignard
Gerard Adam
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of ATE124047T1 publication Critical patent/ATE124047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT91403116T 1990-11-20 1991-11-20 Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen. ATE124047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9014381A FR2669336B1 (fr) 1990-11-20 1990-11-20 Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
ATE124047T1 true ATE124047T1 (de) 1995-07-15

Family

ID=9402340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91403116T ATE124047T1 (de) 1990-11-20 1991-11-20 Oxazolopyridinderivate, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen.

Country Status (12)

Country Link
US (1) US5130311A (de)
EP (1) EP0487408B1 (de)
JP (1) JPH0735371B2 (de)
AT (1) ATE124047T1 (de)
AU (1) AU640289B2 (de)
CA (1) CA2055859A1 (de)
DE (1) DE69110625T2 (de)
FR (1) FR2669336B1 (de)
IE (1) IE914012A1 (de)
NZ (1) NZ240656A (de)
PT (1) PT99557A (de)
ZA (1) ZA919181B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663929A1 (fr) * 1990-06-29 1992-01-03 Adir Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5618819A (en) * 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
CA2400578C (en) 2000-02-08 2007-01-02 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2283842T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CA2585165A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
CN117813325A (zh) 2021-08-27 2024-04-02 H.隆德贝克有限公司 使用抗cgrp抗体治疗丛集性头痛
WO2025262247A1 (en) 2024-06-21 2025-12-26 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026120069A1 (en) 2024-12-05 2026-06-11 H. Lundbeck A/S Humanized anti-pacap antibody and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929809A (en) * 1970-06-26 1975-12-30 Ciba Geigy Corp Oxazolo-{8 4,5-b{9 -pyridine-2-ones and -2-thiones as intermediates
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
FR2650591B1 (fr) * 1989-08-07 1991-11-15 Science Organisation Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL98527A0 (en) * 1990-06-18 1992-07-15 Merck & Co Inc Pyridones,processes for their preparation and pharmaceutical compositions containing them
NZ238576A (en) * 1990-06-18 1994-12-22 Merck & Co Inc Pyridinone derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
NZ240656A (en) 1992-11-25
CA2055859A1 (fr) 1992-05-21
PT99557A (pt) 1992-10-30
FR2669336B1 (fr) 1993-01-22
US5130311A (en) 1992-07-14
JPH04283566A (ja) 1992-10-08
ZA919181B (en) 1992-08-26
DE69110625T2 (de) 1996-02-22
FR2669336A1 (fr) 1992-05-22
EP0487408A1 (de) 1992-05-27
DE69110625D1 (de) 1995-07-27
IE914012A1 (en) 1992-05-20
AU8794291A (en) 1992-05-21
JPH0735371B2 (ja) 1995-04-19
EP0487408B1 (de) 1995-06-21
AU640289B2 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
DE69110625D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ATE128458T1 (de) Naphtylalkylamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69100079D1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE174920T1 (de) Pyridothiadiazine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE59407494D1 (de) 4-aminopyridine, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
ATE13056T1 (de) Indanderivate, verfahren zu ihrer herstellung und sie enthaltende zusammensetzungen.
ATE165601T1 (de) Benzopyran-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als zellenschutzmittel
ATE145899T1 (de) Trimetazidinederivate, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen
ATE152707T1 (de) Neue naphthalin-amide und sulfonamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE193531T1 (de) Phenyl-carboxamide-isoxazole-derivate und salze, verfahren zu ihrer herstellung ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen die sie enthalten
ATE8401T1 (de) Anthracyclin-glycoside, verfahren zu ihrer herstellung, zwischenprodukte und ihre herstellung und arzneimittel.
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE160338T1 (de) Alpha aminosäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
AU639154B2 (en) New imidazole compounds, a process for the preparation thereof, and pharmaceutical compositions containing them
ATE125538T1 (de) Thiochromanderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE170520T1 (de) Eburnan-derivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE140216T1 (de) (cyclohexyl)alkenderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE153995T1 (de) Cyclizierte analoge der fettsäurenmetaboliten, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE23528T1 (de) +/- 2-((3,4-methylenedioxy)phenethyl)-5-((3carboxamido-4-hydroxy)-alpha-hydroxybenzyl)pyrrolidine, pharmazeutische zusammenstellungen die sie enthalten, verfahren zur herstellung und deren zwischenprodukte.
ATE82289T1 (de) 1-hydroxyalkylxanthine, verfahren zu ihrer herstellung und sie enthaltende medikamente.
ZA933942B (en) Pyrrolothienopyrazine compounds, processes for the preparation thereof and pharmaceutical compositions containing them
DE69016378D1 (de) Substituierte Benzothiazolinone, ihre Herstellung und sie enthaltende pharmazeutische Zusammenstellungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee